Mineralys Therapeutics Completes $192M IPO
- Mineralys Therapeutics, a US-based clinical-stage biopharmaceutical company, completed last Friday a $192m initial public offering (IPO) on the Nasdaq Global Select Market at $16.00 per share
- The share price rose to $18.44 (+15.25%) at the closing on its first day of trading
- Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone
- Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension
- The company has completed a Phase 2 study in uncontrolled and resistant hypertension and has announced positive results in November 2022
- The IPO financing will support the company to advance its pivotal program in uncontrolled hypertension in the United States
